Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., Steensma, D. P., Kreuzer, K. A., Godley, L. A., Collins, R., Atallah, E. L., Azarnia, N., Garcia-Manero, G. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036901628